Phase II study of photodynamic therapy (PDT) for malignant meningioma
Phase 2
Recruiting
- Conditions
- malignant/atypical meningioma
- Registration Number
- JPRN-UMIN000031156
- Lead Sponsor
- Kobe University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Subject is known, suspected or has history of intolerance or allergy to Talaporfin Sodium. (2) Subjects with porphyria. (3) Severe liver and renal dysfunction. (4) Subject with allergies such as a drug hypersensitivity constitution. (5) Pregnancy or Breast-Feeding: Pregnant or breast-feeding women will not be entered on this study, as risks of fetal and teratogenic adverse effects of Talaporfin Sodiumare not known.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression free time of the laser irradiation site
- Secondary Outcome Measures
Name Time Method